Diagnostic Approach to the Patients with Suspected Primary Immunodeficiency.

Primary immunodeficiency disorders antibody deficiency autoimmunity combined immunodeficiency enteropathy infection.

Journal

Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157

Informations de publication

Date de publication:
2020
Historique:
received: 22 02 2019
revised: 16 06 2019
accepted: 04 08 2019
pubmed: 29 8 2019
medline: 20 11 2020
entrez: 29 8 2019
Statut: ppublish

Résumé

Primary immunodeficiency diseases (PIDs) are a group of more than 350 disorders affecting distinct components of the innate and adaptive immune systems. In this review, the classic and advanced stepwise approach towards the diagnosis of PIDs are simplified and explained in detail. Susceptibility to recurrent infections is the main hallmark of almost all PIDs. However, noninfectious complications attributable to immune dysregulation presenting with lymphoproliferative and/or autoimmune disorders are not uncommon. Moreover, PIDs could be associated with misleading presentations including allergic manifestations, enteropathies, and malignancies. Timely diagnosis is the most essential element in improving outcome and reducing the morbidity and mortality in PIDs. This wouldn't be possible unless the physicians keep the diagnosis of PID in mind and be sufficiently aware of the approach to these patients.

Sections du résumé

BACKGROUND AND OBJECTIVE OBJECTIVE
Primary immunodeficiency diseases (PIDs) are a group of more than 350 disorders affecting distinct components of the innate and adaptive immune systems. In this review, the classic and advanced stepwise approach towards the diagnosis of PIDs are simplified and explained in detail.
RESULTS RESULTS
Susceptibility to recurrent infections is the main hallmark of almost all PIDs. However, noninfectious complications attributable to immune dysregulation presenting with lymphoproliferative and/or autoimmune disorders are not uncommon. Moreover, PIDs could be associated with misleading presentations including allergic manifestations, enteropathies, and malignancies.
CONCLUSION CONCLUSIONS
Timely diagnosis is the most essential element in improving outcome and reducing the morbidity and mortality in PIDs. This wouldn't be possible unless the physicians keep the diagnosis of PID in mind and be sufficiently aware of the approach to these patients.

Identifiants

pubmed: 31456526
pii: EMIDDT-EPUB-100491
doi: 10.2174/1871530319666190828125316
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

157-171

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Marzieh Tavakol (M)

Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Department of Allergy and Clinical Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Mahnaz Jamee (M)

Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran.

Gholamreza Azizi (G)

Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Homa Sadri (H)

Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Department of Allergy and Clinical Immunology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Yasser Bagheri (Y)

Clinical Research Development Unit (CRDU), 5 azar Hospital, Golestan University of Medical Sciences, Gorgan, Iran.

Majid Zaki-Dizaji (M)

Legal Medicine Research Center, Legal Medicine Organization, Tehran, Iran.

Fatemeh Sadat Mahdavi (FS)

Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran.

Farhad Jadidi-Niaragh (F)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Sanaz Tajfirooz (S)

Department of Pediatrics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Ali N Kamali (AN)

CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran.

Fatemeh Aghamahdi (F)

Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Department of Pediatric Endocrinology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Shahab Noorian (S)

Department of Pediatric Endocrinology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Habibeh Taghavi Kojidi (HT)

Department of Pediatric Endocrinology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Mehdi Mosavian (M)

Non-communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran.
Department of Gastroenterology and Hepatology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Rahman Matani (R)

Department of Gastroenterology and Hepatology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Elahe Dolatshahi (E)

Department of Rheumatology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Kumars Porrostami (K)

Department of Pediatrics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Nasrin Elahimehr (N)

Department of Pediatrics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Marzie Fatemi-Abhari (M)

Department of Pediatrics, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Laleh Sharifi (L)

Uro- Oncology Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Reza Arjmand (R)

Department of Infectious Disease, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran.

Sabahat Haghi (S)

Department of Hematology & Oncology, School of Medicine, Alborz university of medical sciences, Karaj, Iran.

Hamed Zainaldain (H)

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Reza Yazdani (R)

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Mohammadreza Shaghaghi (M)

Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins Hospital, Baltimore, MD, United States.

Hassan Abolhassani (H)

Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden.

Asghar Aghamohammadi (A)

Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH